Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vepalimomab

X
Drug Profile

Vepalimomab

Alternative Names: Anti-VAP-1 mouse monoclonal antibody; Anti-VAP-I mouse monoclonal antibody; Vapantix

Latest Information Update: 02 Mar 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioTie Therapies
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dermatitis; Inflammatory bowel diseases; Psoriasis

Most Recent Events

  • 06 Nov 2002 BioTie Therapies and Carbion have merged with Contral Pharma
  • 08 Sep 2002 Discontinued - Clinical-Phase-Unknown for Inflammatory bowel disease in Finland (unspecified route)
  • 08 Sep 2002 Discontinued - Phase-I/II for Dermatitis in Finland (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top